Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

ducts with strong intellectual property and exciting growth prospects. We continue to increase the global reach of our business, and now have a presence in 26 countries worldwide compared to nine countries four years ago.

We have also developed a promising pipeline with encouraging recent news. With the receipt of a Complete Response Letter from the US Food and Drug Administration ("FDA") for INTUNIV, we are confident that we will quickly come to agreement on the final wording of the product label and will launch in the fourth quarter of 2009 as planned. We are also initiating Phase 2 pilot clinical trials to assess the efficacy and safety of VYVANSE in non ADHD ("Attention Deficit Hyperactivity Disorder") indications. Our HGT pipeline has been strengthened by positive results from our trial of velaglucerase in naïve Gaucher patients. A treatment protocol for early access has been approved by the FDA and the agency has approved Fast Track designation for the product. Rolling review of the New Drug Application ("NDA") has started.

Our core portfolio has made good progress in the quarter. We are pleased with the performance of VYVANSE as it has retained market share during the historically quieter summer vacation season in contrast to other branded ADHD treatments that have lost market share. We are anticipating the benefits of the back to school season for VYVANSE and are looking forward to increased sales momentum from our co-promote agreement with GSK for adult ADHD. We are also expecting further positive newsflow from our pipeline during the second half of this year.

Supported by pro-active cost management, our business is well placed to deliver on our unchanged guidance framework for 2009 and looking ahead we reiterate our aspiration of growing sales in the mid-teens range on average between 2009 and 2015."

    Second Quarter 2009 Unaudited Results

                                  
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... patient monitors and sensors, reported a net loss of $245,000 ... $6 million. , ,Sales were down from nearly $6.6 million ... also down, and the firm's net loss came down from ... at about $3.7 million. , ,Criticare (AMEX:CMD) said that several ...
... Now that spring is in gear, women looking for new ... a "shorts and tee shirts" alternative to the traditional conference ... until Sunday, with yoga in the mornings and two full ... of summer camp. ... Your physical surroundings and the things ...
... the Alzheimer's disease drug market in the United ... percent annually for the next five years. , ... Markets for Alzheimer's Disease Medications 2005," include Pfizer, ... Alzheimer's drug market that generated more than $1.3 ...
Cached Biology Technology:Women in technology confab comes to Wisconsin 2Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... at the University of Liverpool has found how worms ... with the body. , Dr Paolo Paoletti, alongside his ... mathematical model for earthworms and insect larvae which challenges ... get around. , The most widely accepted model is ... that the central brain of these creatures generates rhythmic ...
(Date:8/19/2014)... available in French . ... and RISKS of physical activity in children,Today the Canadian ... promotion of childhood physical activity and published their position ... and Metabolism ( APNM ). This position ... area of risk of physical activity for children and ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Secrets of how worms wriggle uncovered 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... Scientists who have determined how much carbon is stored ... be used to accelerate global discussion about the strategy ... In an era of competing land use demands, the ... are abundant sources of other ecological goods and services ...
... College of Clinical Pharmacology (ACCP) has awarded ... director of Pediatric Clinical Pharmacology at Children,s National ... Dr. van den Anker, a neonatologist by training, ... contributions to pediatric clinical pharmacology," according to the ...
... 8, 2008-- The McClellan Nuclear Radiation Center (MNRC) in ... to detect corrosion and defects in aircraft structure using ... currently helping soil scientists understand the function of plant ... Scientists at the University of California in Davis present ...
Cached Biology News:Scientists point to forests for carbon storage solutions 2Scientists point to forests for carbon storage solutions 3Scientists point to forests for carbon storage solutions 4Scientists point to forests for carbon storage solutions 5US Air Force technology helps scientists understand plant root function 2
...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: